Genflow Biosciences Share Discussion Threads

[moneymunch] 28/7/2024 07:46

Shots in the arm for Britain and biotech

Investment trusts to target recoveries in the UK and biotech.

July 25, 2024

UK re-rate long overdue.

Signs of recovery in biotech.

Two of the big sound bites of recent years were “broken Britain” and “trust the science.” From an investment perspective it may be time to discard the first and keep faith in the second of these phrases. Following a tough decade there are some deep value opportunities especially among smaller UK-listed companies. In the case of life sciences and biotechnology, the industry is showing signs of recovering health after valuations and fundraising were hit by the period of rapid interest rate hikes.

Recent PMI data, especially in manufacturing, suggests that the UK recovery is on track. Greater political certainty is widely perceived as being of benefit in encouraging companies to make capex decisions which will provide a further boost to UK growth. Of course, the flipside of increased demand for resources and labour is that this can have an inflationary effect in the short term, but not necessarily in the components of indicators that are worrying policymakers.

[moneymunch] 26/7/2024 20:38

PPPlease Eric!!! :-)))

[bri15] 26/7/2024 12:54

Massive rise coming here, buyers loading up!

[moneymunch] 24/7/2024 19:09

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,683 followers
7h

The pet care industry has exploded in recent years, with dog focused products seizing the majority of the market.

Treatments promising to extend canine companions' lifespans, such as Genflow Biosciences (LON:GENF) (OTCQB:GENFF) innovative #SIRT6 treatment, are gaining significant attention from animal lovers and investors alike.

Learn more about the promising treatments:

#longevity #veterinarymedicine #biotech


The next leap in pet health: longevity drugs for dogs

[moneymunch] 23/7/2024 19:42

Looking forward to the bounce in sp, big news could drop at anytime. Gla Holders:-)

[moneymunch] 23/7/2024 19:35

Britain can become the global leader in longevity science, Lord Lebedev has told Parliament.


23/7/24

Longevity research ‘can unlock huge benefits’ for Britain as it tackles an ageing population

‘As life expectancy has increased, the proportion of time spent in good health is going down. We must urgently develop a new approach to medicine’ - Lord Lebedev

He stressed that longevity research could “unlock huge benefits” for the UK as it faces the challenges of an ageing population. “Our country faces a medical crisis,” he said. “As life expectancy has increased, the proportion of time spent in good health is going down. We must urgently develop a new approach to medicine.”

......

“The discovery of the 12 hallmarks of ageing, including the loss of stem cells and metabolic dysregulation, are central to our understanding of what drives age-related disease,” the crossbench peer told the Upper House.

“A groundbreaking new theory suggests ageing is driven by the loss of vital regulatory information within our cells, rather than primarily accumulating damage over time. Through epigenetic reprogramming, we could potentially reset our body’s tissues to a more functional state. Scientific studies have already reversed vision loss in mice and human trials are set to begin next year.”

The peer highlighted drugs being developed to reverse aspects of ageing.

“Cutting-edge breakthroughs like these, driven by labs right here in the UK, are informing how we tackle the underlying factors behind ageing, rather than just tackling symptoms,” he added. He stressed further: “We stand at the precipice of a medical revolution, catalysed by medical monitoring devices, genomics, and our understanding of what drives ageing.

“Britain can become the global leader in longevity science, and capturing this beachhead will benefit us both socially and economically.” He emphasised that the science is now “moving as rapidly as the AI revolution and will be similarly, if not more impactful”.

[moneymunch] 12/7/2024 19:29

I'm pretty sure, just about every share that's been sold over the last couple of weeks or so, bringing the share price down to where it is, despite the low and insignificant selling volume, have been bought, almost under the radar!!!??? Gla holders and C'mon England!!! :')))

[prashaprash] 11/7/2024 19:28

MASH (previously known as NASH) is number 1 cause on the list for patient who received Liver transplant in UK.Also obesity is on rise in western world and 20% of those fatty liver are at the risk of liver damage.Quality life what we are aiming for and Liver plays important role in metabolism as whatever we eat passes through Liver at first.

[smithie6] 10/7/2024 12:04

ok, thanks for that reply.

[moneymunch] 10/7/2024 10:48

Lol, you tell that to the millions around the world who are suffering liver disease and associated ailments, although Genflow's Sirt6 gene is thought to influence multiple disease targets and so could be a panacea for multiple diseases leading to extended lifespan and more importantly extended healthspan, and so positive data from next year's planned human clinical trials is likely to make my investment here worth many £100k's regardless of how long the rest of the organ’s might last. Gl :-)

Ps in the meantime, plenty of newsflow expected soon including initiation confirmation of the upcoming dog trials. Woof woof!!! :-)

[smithie6] 10/7/2024 09:45

but if the liver can survive to say 200 years, is that much use if all the other body organs have failed ?

[moneymunch] 09/7/2024 11:59

The following publication only just released is by the Duke University School of Medicine, one of Genflow's academic collaborative partners, focused on "ferroptosis" which appears to be highly influenced by Sirt6. Gla holders. :-)


Researchers successfully rejuvenate aging livers in preclinical study

July 8, 2024 —

Researchers have been able to reverse age-related damage to liver cells in mice and in human cell cultures in a new study.

The study homes in on ferroptosis — a form of iron-dependent cell death — as an age-related process affecting a set of key cells in the liver, called ‘hepatocytes.’

Its authors found gene clusters associated with this process in both mice and human cells.

The takeaway is that it may be possible to reverse aging in affected liver cells through pharmaceutical interventions.



.....

The roles of sirtuins in ferroptosis

[moneymunch] 04/7/2024 07:08

Yep, low volume selling pi's dragging the share price down as we await the next UPdate, and will hopefully all regret selling their shares soon enough. Big news at anytime. Gla Holders!!! ;-)

[cyberbub] 03/7/2024 14:01

Disappointing to see the drop here, but it's just low-volume summer trading in an illiquid share. Come back in Sept IMO - unless there's some mega news before then, which is always possible!

[moneymunch] 29/6/2024 06:59

Eric confirms they're ready to iniate the dog trial , " a program with possible reward at a very short time, with proof of concept much faster than in human and within a year could reach some interesting collaboration with a large Vet Pharma Company." ...Gla ;-)

[moneymunch] 27/6/2024 19:16

Absolutely Northeast, the market response was almost non-existent following the previous updates on funding etc, and took a few days before the UPward surge from 1.4p...fingers crossed for something similar and every chance of more news in the pipeline, confirmation of a Vet Partner to finance the Dog trial would see the share price explode UPwards. Gl :-)

[moneymunch] 27/6/2024 18:51

Ps the same Nir Barzilai from Sirtlabs. Gla :-)

SIRT6: The protein that talks the talk and walks the walk

SIRT6: The protein that talks the talk and walks the walk


Partner content
Nir Barzilai on keeping longevity research relevant to humans, developing gerotherapeutics and making the best decisions.
Last month, US-Israeli startup SIRTLab announced the appointment of leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, adding additional longevity kudos to a company founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research.

[moneymunch] 27/6/2024 18:46

Could the approval of longevity drugs for dogs pave the way for human longevity drugs?

The possibility of extending dogs’ lives with longevity drugs has also raised the possibility that scientists might be able to find drugs with the same life-extending effects in people. Dogs are actually known to be very good models for human aging – far better than mice models, in fact.

Nir Barzilai, professor of genetics and medicine at the Albert Einstein College of Medicine in New York, explained in an interview with The Guardian, that this is because they “share our environment in such a respect that their microbiota is more similar to their owners than to other dogs.” Essentially, we eat similar foods and follow a similar lifestyle, plus our metabolisms work in much the same way, and we suffer the same diseases, such as cancer and cognitive decline.

Many longevity biotech companies are already on the case when it comes to developing anti-aging drugs for humans. However, they are yet to be proven in a clinical setting. If longevity drugs for dogs could help speed up the development of human anti-aging drugs, then the approval of Loyal’s candidates could be even more of a milestone achievement.

[northeast14] 27/6/2024 18:30

Great updates today. Markets asleep. Eric just keeps giving huge investor value here. An absolute steal at these low prices

[moneymunch] 27/6/2024 18:12

Upcoming - happening or appearing soon : forthcoming, approaching.

[moneymunch] 27/6/2024 18:06

Genflow's Product Pipeline on their website states "Pivotal Trial Anti-aging for Dogs with Vet Partner", and as Eric stated today "it's upcoming clinical dog trial", suggests they might have a partner in place if the clinical trial is "upcoming "!!!??? Gla.:-)

[moneymunch] 27/6/2024 07:29

very positive and encouraging and great to hear the dog trials are back in focus, which must have a very high chance of attracting a JV partner from the Major players within the veterinary and canine world. Gla :-)

......

Dog Longevity Startup Loyal Secures $45 Million in Funding

The San Francisco company is one of several longevity startups attracting the attention of venture-capital investors

March 21, 2024

Biotech startup Loyal has raised $45 million in equity to help bring its first longevity drug for dogs to market.

[moneymunch] 27/6/2024 06:14

Great news for todays AGM.....Gla holders ;-)

[moneymunch] 27/6/2024 06:03

RNS Number : 0280U

Genflow Biosciences PLC

27 June 2024

27 June 2024

Genflow Biosciences Plc

Genflow Biosciences Strengthens Pre-Clinical Efforts

with FDA Guidance and CDMO and CRO Selection

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to report advancements in its pre-clinical programs.

Genflow has initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP).

Genflow is also in the process of selecting Contract Research Organizations (CROs) to conduct its upcoming dog clinical trial, aimed at studying its promising drug candidate, GF-1004. The Company is currently evaluating requests for proposals (RFPs) and is working diligently to finalize a definitive agreement next month.

In addition, Genflow has received research guidance from the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT). The Company submitted a comprehensive briefing package detailing all preclinical (in vitro and in vivo) studies conducted with its lead drug candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH).

The FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (POC) studies. These studies will inform the definitive POC, toxicology, and biodistribution studies necessary for eventual clinical trials. Detailed summaries of the products used in each animal study and their comparability to the intended clinical product are to be included.

Dr. Eric Leire, CEO of Genflow commented: " We are excited by the momentum we have built in moving forward with our pre-clinical programs and the guidance received from the FDA. This encouragement reinforces our commitment to developing effective therapeutic solutions for age-related diseases. As we move forward with our dog clinical trials, we remain focused on our mission to improve healthspan."

[moneymunch] 26/6/2024 17:17

For markets: Betting on biotech's bounce back.

The investment in Formation Bio signals a broader recovery in the biotech sector. With inflationary pressures easing and confidence building in the US economy's smooth descent, investors are flocking back to biotech, anticipating innovative breakthroughs. This trend suggests a revitalization of venture capital flow into biotech firms, supported by promising trial data and advanced AI applications. Investors should keep an eye on these developments for potential growth opportunities.